Fosun Pharma (600196) Announces Acceptance of Subsidiary’s New Drug Registration Application

Bulletin Express

02/13

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196) disclosed that its subsidiary, Jinzhou Avanc Pharmaceutical Co., Ltd., has recently received acceptance from the National Medical Products Administration for the drug registration application of Moxetomidate Hydrochloride Injection (ET-26). This Class 1 chemical medicine, recognized as a National Major Scientific and Technological Special Project for “Significant Drugs Development” in 2014, targets the induction and maintenance of anesthesia during short surgical procedures.

According to the announcement, Fosun Pharma’s cumulative research and development investment for this project stands at RMB 189.00 million (unaudited) as of January 2026. Market data indicates that drugs for similar uses recorded total sales of RMB 4,238.00 million in 2024. The acceptance of this application does not have a material impact on the group’s current financial results.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1137162235"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1137162235\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1137162235?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 18:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137162235","market":"hk","top_or_hot":-1,"title":"Fosun Pharma (600196) Announces Acceptance of Subsidiary’s New Drug Registration Application","media":"Bulletin Express","content":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196) disclosed that its subsidiary, Jinzhou Avanc Pharmaceutical Co., Ltd., has recently received acceptance from the National Medical Products Administration for the drug registration application of Moxetomidate Hydrochloride Injection (ET-26). This Class 1 chemical medicine, recognized as a National Major Scientific and Technological Special Project for “Significant Drugs Development” in 2014, targets the induction and maintenance of anesthesia during short surgical procedures.</p>\n<p>According to the announcement, Fosun Pharma’s cumulative research and development investment for this project stands at RMB 189.00 million (unaudited) as of January 2026. Market data indicates that drugs for similar uses recorded total sales of RMB 4,238.00 million in 2024. The acceptance of this application does not have a material impact on the group’s current financial results.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma (600196) Announces Acceptance of Subsidiary’s New Drug Registration Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma (600196) Announces Acceptance of Subsidiary’s New Drug Registration Application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-13 18:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196) disclosed that its subsidiary, Jinzhou Avanc Pharmaceutical Co., Ltd., has recently received acceptance from the National Medical Products Administration for the drug registration application of Moxetomidate Hydrochloride Injection (ET-26). This Class 1 chemical medicine, recognized as a National Major Scientific and Technological Special Project for “Significant Drugs Development” in 2014, targets the induction and maintenance of anesthesia during short surgical procedures.</p>\n<p>According to the announcement, Fosun Pharma’s cumulative research and development investment for this project stands at RMB 189.00 million (unaudited) as of January 2026. Market data indicates that drugs for similar uses recorded total sales of RMB 4,238.00 million in 2024. The acceptance of this application does not have a material impact on the group’s current financial results.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1137162235","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137162235","pubTimestamp":1770976947,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196) disclosed that its subsidiary, Jinzhou Avanc Pharmaceutical Co., Ltd., has recently received acceptance from the National...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"复星医药(600196)公告子公司新药注册申请受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196) disclosed that its subsidiary, Jinzhou Avanc Pharmaceutical Co., Ltd., has recently received acceptance from the National Medical Products Administration for the drug registration application of Moxetomidate Hydrochloride Injection (ET-26). This Class 1 chemical medicine, recognized as a National Major Scientific and Technological Special Project for “Significant Drugs Development” in 2014, targets the induction and maintenance of anesthesia during short surgical procedures.\nAccording to the announcement, Fosun Pharma’s cumulative research and development investment for this project stands at RMB 189.00 million (unaudited) as of January 2026. Market data indicates that drugs for similar uses recorded total sales of RMB 4,238.00 million in 2024. The acceptance of this application does not have a material impact on the group’s current financial results.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}